Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow XENE
Xenon Pharmaceuticals Inc. (XENE) P/E ratio
Xenon Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 16.5× (October 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| DNLI Denali Therapeutics Inc. compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.5× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)